Published on December 15, 2009 at 11:38 PM
BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment
and supportive care of cancer and AIDS patients, today announces the
approval from the French Drug Agency (AFFSSaPS) to enter Phase II
clinical trial for clonidine Lauriad® in radiotherapy and
chemotherapy-induced oral mucositis and the approval from Danish and
Slovene Agencies to enter Phase I clinical trial for AMEPTM
in invasive melanoma.
Clonidine Lauriad® uses the innovative muco-adhesive
technology validated with Loramyc® and more recently with
acyclovir Lauriad®. This new product is dedicated to the
prevention and the treatment of radiotherapy and chemotherapy-induced
oral mucositis in cancer patients. Clonidine Lauriad® is part
of the supportive care pipeline BioAlliance Pharma is building. This
product presents the opportunity to satisfy an unmet medical need.
Patent application has been filed.
AMEP™, anti-invasive biotherapy, is dedicated to metastatic and invasive
melanoma, an advanced skin cancer refractory to most treatments. Its
original mechanism of action targets specific receptors involved in
tumor growth and in tumor angiogenesis. This project is supported by
OSEO (the French state innovation agency) which finances technological
breakthrough projects and has been granted €6.4 million to participate
in its clinical development.
In both trials, the first patients should be recruited early 2010.
« With fentanyl Lauriad®, clonidine
Lauriad® and AMEPTM,
BioAlliance Pharma’s Teams have fulfilled our objective to bring these
three products into clinical phase in 2009 while using our industrial
know-how of Lauriad® mucoadhesive technology,
and confirming significant progress in the development of our new cancer
chemical entities”, comments Dominique Costantini, President and CEO
of BioAlliance Pharma.
http://www.bioalliancepharma.com/